Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep:230:108816.
doi: 10.1016/j.clim.2021.108816. Epub 2021 Aug 2.

BTK inhibitors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A systematic review

Michael Stack  1 , Keith Sacco  2 , Riccardo Castagnoli  1 , Alicia A Livinski  3 , Luigi D Notarangelo  1 , Michail S Lionakis  4
Affiliations

BTK inhibitors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A systematic review

Michael Stack et al. Clin Immunol. 2021 Sep.

Abstract

Introduction: The Bruton tyrosine kinase (BTK) regulates B cell and macrophage signaling, development, survival, and activation. Inhibiting BTK has been hypothesized to ameliorate lung injury in patients with severe COVID-19, however clinical outcome data is inconclusive.

Objective: To evaluate the clinical outcomes of BTK inhibitors (BTKinibs) in patients with COVID-19.

Evidence review: We searched PubMed, Embase, and Web of Science:Core on December 30, 2020. Clinical studies with at least 5 COVID-19 patients treated with BTKinibs were included. Case reports and reviews were excluded.

Findings: 125 articles were identified, 6 of which met inclusion criteria. The most common clinical outcomes measured were oxygen requirements (4/6) and hospitalization rate or duration (3/6). Three studies showed decreased oxygen requirements in patients who started or continued BTKinibs. All three studies that evaluated hospitalization rate or duration found favorable outcomes in those on BTKinibs.

Conclusions and relevance: BTKinib use was associated with decreased oxygen requirements and decreased hospitalization rates and duration.

Keywords: Acalabrutinib; Acute respiratory distress syndrome; Bruton's tyrosine kinase; COVID-19; Cytokine storm; Hospitalization; Ibrutinib; SARS-CoV-2; X-linked agammaglobulinemia.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flow diagram of inclusion of studies in our analysis.
See this image and copyright information in PMC

Update of

References

    1. Baloch S., et al. The coronavirus disease 2019 (COVID-19) pandemic. Tohoku J. Exp. Med. 2020;250(4):271–278. - PubMed
    1. Ciceri F., et al. Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy. Clin. Immunol. 2020;217:108509. - PMC - PubMed
    1. McGonagle D., et al. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun. Rev. 2020;19(6):102537. - PMC - PubMed
    1. Ragab D., et al. The COVID-19 cytokine storm; what we know so far. Front. Immunol. 2020;11:1446. - PMC - PubMed
    1. Huang C., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. - PMC - PubMed